Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Samsung Biologics announced plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. mRNA has been the technology of choice for ...
read more
Wednesday, December 13, 2017
Samsung BioLogics has been licensed by the Europe’s EMA for the first monoclonal antibody Drug Substance at its second plant.
read more
Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the FDA for its second plant.
read more
Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year's BioProcess International Conference and ...
read more
Monday, February 24, 2020
Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.
read more
Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline.
read more
Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins. Under the ...
read more
Monday, February 11, 2019
Samsung Bioepis announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.
read more
Wednesday, November 06, 2019
Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept).
read more
Samsung Biologics, a leading contract development and manufacturing organization, announced strong financial results for the second quarter of 2022.
read more
Wednesday, September 16, 2020
Sai Life Sciences announced the addition of cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA.
read more
Tuesday, September 10, 2019
Nichi-Iko and Sagent announced their Canadian subsidiary, Omega Laboratories, has been found acceptable for manufacturing FDA-approved products.
read more
Tuesday, November 16, 2021
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led ...
read more
Sigma-Aldrich® Corporation's (NASDAQ: SIAL) custom manufacturing and services business unit, SAFC Commercial (www.sigma-aldrich.com/safc), has entered into a collaborative technology agreement with BioTools Inc. (www.btools.com). The partnership ...
read more
ST. LOUIS, March 5, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC (www.safcglobal.com), is expanding its line of PharmaGrade products with the addition of ...
read more